Rhodes Pharmaceuticals, L.P.

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Activity

Key Events

Dec 14, 2023FDADilaudid — HYDROMORPHONE HYDROCHLORIDE

Mar 3, 2023FDADilaudid — HYDROMORPHONE HYDROCHLORIDE

Jan 16, 2020FDADilaudid — DILAUDID

Sep 1, 2016TrialA 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD

Jul 30, 2016TrialPharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

1 patent group across drugs · Source: FDA Orange Book

DrugExpires

DilaudidApr 23, 2032

Regulatory

Regulatory Timeline

19921 event

FDADec 7

Dilaudid — DILAUDID

Application NDA019891 (NDA)

20041 event

FDASep 24

Dilaudid — PALLADONE

Application NDA021044 (NDA)

20071 event

FDANov 9

Dilaudid — DILAUDID

Application NDA019892 (NDA)

20101 event

FDAMar 1

Dilaudid — EXALGO

Application NDA021217 (NDA)

20201 event

FDAJan 16

Dilaudid — DILAUDID

Application NDA019034 (NDA)

20232 events

FDADec 14

Dilaudid — HYDROMORPHONE HYDROCHLORIDE

Application NDA217812 (NDA)

FDAMar 3

Dilaudid — HYDROMORPHONE HYDROCHLORIDE

Application NDA200403 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)